Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and AZD6738 in Relapsed SCLC
NCT04361825Phase 2Completed
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceralasertib in small cell lung cancer (SCLC). Primary endpoint: Objective Response Rate up to 30 months. Started Jun 2020; status: completed.
02
Drugs
ceralasertib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04361825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361825.